THELMA Therapeutics Co., Ltd. (KOSE:A015540) agreed to acquire 30% stake in Closed Joint Stock Company NanoBrahiTek from Otkrytie LLC for KRW 20.1 billion on December 31, 2020. Under the terms, THELMA Therapeutics will acquire 3,000 shares of NanoBrahiTek by issuance of convertible bonds and payment of cash. In a related transaction, THELMA Therapeutics Co., Ltd. (KOSE:A015540) agreed to acquire 21% stake in Closed Joint Stock Company NanoBrahiTek from Zvezda JSC for KRW 14 billion. Post completion of these transactions, THELMA Therapeutics Co., Ltd will hold 51% stake in Closed Joint Stock Company NanoBrahiTek. NanoBrahiTek reported total assets of KRW 4.8 billion, total liabilities of KRW 6.6 million, total equity of KRW 4.8 billion and net income of KRW 1billion in 2019. On December 31, 2020, the Board of THELMA Therapeutics resolved this transaction. This transaction is expected to close on August 31, 2021. As of August 31, 2021, the transaction is expected to close on October 29, 2021.